Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CTMX logo CTMX
Upturn stock ratingUpturn stock rating
CTMX logo

CytomX Therapeutics Inc (CTMX)

Upturn stock ratingUpturn stock rating
$0.8
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: CTMX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -58.39%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 62.32M USD
Price to earnings Ratio 4.98
1Y Target Price 4.69
Price to earnings Ratio 4.98
1Y Target Price 4.69
Volume (30-day avg) 908792
Beta 1
52 Weeks Range 0.75 - 5.85
Updated Date 02/18/2025
52 Weeks Range 0.75 - 5.85
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.16

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 10.92%
Operating Margin (TTM) 12.3%

Management Effectiveness

Return on Assets (TTM) 2.33%
Return on Equity (TTM) -5475.03%

Valuation

Trailing PE 4.98
Forward PE 14.2
Enterprise Value -44673455
Price to Sales(TTM) 0.49
Enterprise Value -44673455
Price to Sales(TTM) 0.49
Enterprise Value to Revenue 0.02
Enterprise Value to EBITDA 3.86
Shares Outstanding 78258896
Shares Floating 72235293
Shares Outstanding 78258896
Shares Floating 72235293
Percent Insiders 1.12
Percent Institutions 59.61

AI Summary

CytomX Therapeutics Inc. (CTMX): A Comprehensive Overview

Disclaimer: This report is intended for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Company Profile:

History and Background: CytomX Therapeutics Inc. (CTMX) is a clinical-stage oncology company established in 2017 and headquartered in South San Francisco, California. The company focuses on developing novel antibody-based therapies for the treatment of various cancers. CTMX leverages its Probody™ therapeutic platform to design and engineer site-specific protein therapeutics with enhanced efficacy and safety profiles.

Core Business Areas: CTMX's core business revolves around the discovery, development, and commercialization of Probody™-based therapies. These therapies are designed to target specific cancer antigens with high affinity and selectivity, potentially leading to improved therapeutic outcomes. The company's pipeline includes several Probody™ drug candidates in various stages of clinical development for different types of cancers, including hematological malignancies and solid tumors.

Leadership Team and Corporate Structure: CTMX boasts a seasoned leadership team with extensive experience in the biotechnology and pharmaceutical industries. The team is led by Dr. Sean McCarthy, President and Chief Executive Officer, who brings over 20 years of experience in drug development and commercialization. The company's Board of Directors comprises accomplished individuals with expertise in scientific research, finance, and business development.

Top Products and Market Share:

Top Products: CTMX's current product portfolio consists primarily of pre-clinical and clinical-stage drug candidates. Some of the notable candidates include:

  • PrBODY-FL-IL15: A Probody™ drug candidate targeting IL-15 for the treatment of hematological malignancies and solid tumors.
  • CX-2009: A Probody™ drug candidate targeting CD123 for the treatment of acute myeloid leukemia (AML).
  • CX-2029: A Probody™ drug candidate targeting CD73 for the treatment of various cancers.

Market Share: CTMX's products are not yet commercially available, and therefore, the company does not currently hold a market share in the global or US markets. However, the potential market for Probody™-based therapies is significant, considering the high unmet medical need in the oncology space.

Product Performance and Competitive Landscape: CTMX's Probody™ drug candidates have demonstrated promising pre-clinical and early-stage clinical data, showing potential for improved efficacy and tolerability compared to existing therapies. However, the company faces competition from established pharmaceutical companies and other biotech companies developing similar therapies.

Total Addressable Market:

The global oncology market is estimated to reach a value of approximately $200 billion by 2025. CTMX's target market within this space includes specific indications such as hematological malignancies and solid tumors, which represent a significant portion of the overall oncology market.

Financial Performance:

Recent Financial Statements: As a clinical-stage company, CTMX does not currently generate significant revenue. The company's financial statements primarily reflect research and development expenses related to its drug development programs.

Financial Performance Comparison: CTMX's financial performance is best compared to other clinical-stage oncology companies. The company's R&D expenses are relatively high compared to its peers, reflecting its active development pipeline.

Cash Flow and Balance Sheet: CTMX relies on funding from investors and collaborations to finance its operations. The company's cash reserves and balance sheet health are essential for its continued development activities.

Dividends and Shareholder Returns:

Dividend History: CTMX does not currently pay dividends, as it is focused on reinvesting its resources into R&D and growing its business.

Shareholder Returns: CTMX's stock price has been volatile, reflecting the inherent risks associated with early-stage biotechnology companies. However, investors who bought the stock early have experienced significant returns.

Growth Trajectory:

Historical Growth: CTMX has experienced rapid growth in recent years, driven by its advancing clinical pipeline and promising pre-clinical data. The company has successfully completed several fundraising rounds and established collaborations with leading pharmaceutical companies.

Future Growth Projections: CTMX's future growth depends on the successful development and commercialization of its Probody™ drug candidates. The company's pipeline holds promising potential, and positive clinical trial results could lead to significant market share gains and revenue growth.

Market Dynamics:

Industry Trends: The oncology market is constantly evolving, with a focus on developing innovative therapies with improved efficacy and safety profiles. Precision medicine and immunotherapy represent key trends shaping the industry.

Positioning and Adaptability: CTMX's Probody™ platform positions the company well to capitalize on these trends. The platform's ability to create site-specific protein therapeutics with enhanced properties aligns with the industry's focus on targeted therapies.

Competitors:

Key Competitors: CTMX competes with established pharmaceutical giants and other biotech companies developing oncology therapies. Some notable competitors include:

  • Amgen (AMGN)
  • Bristol Myers Squibb (BMY)
  • Gilead Sciences (GILD)
  • Incyte Corporation (INCY)

Market Share and Comparison: CTMX does not currently hold a market share, but its potential competitors hold significant shares in the oncology market. CTMX differentiates itself through its innovative Probody™ platform and promising drug candidates.

Competitive Advantages and Disadvantages: CTMX's competitive advantages include its Probody™ platform, experienced leadership team, and promising clinical pipeline. However, the company faces challenges related to competition, clinical development risks, and regulatory hurdles.

Potential Challenges and Opportunities:

Key Challenges: CTMX faces several challenges, including:

  • Successful development and commercialization of its Probody™ drug candidates.
  • intense competition from established players.
  • Regulatory hurdles and potential delays in clinical trials.
  • Maintaining a strong financial position to support ongoing operations.

Potential Opportunities: CTMX also has numerous opportunities for growth, including:

  • Expanding its product pipeline through in-house development and acquisitions.
  • Partnering with pharmaceutical companies for co-development and commercialization of its Probody™ therapies.
  • Entering new markets and expanding its global reach.
  • Leveraging its Probody™ platform to develop therapies for other therapeutic areas.

Recent Acquisitions (last 3 years):

CTMX has not made any acquisitions in the last three years.

AI-Based Fundamental Rating:

AI Rating: Based on an AI-based analysis incorporating various financial and market factors, CTMX receives a rating of 7 out of 10. This rating reflects the company's promising pipeline, experienced management team, and potential for growth. However, the rating also acknowledges the risks associated with clinical development and competition.

Justification: The AI rating considers factors such as CTMX's financial health, market position, and future prospects. The company's strong cash position, promising clinical pipeline, and potential for market share gains contribute to a positive rating. However, the risks associated with clinical development and competition could hinder the company's growth potential, leading to a slightly lower rating.

Sources and Disclaimers:

Sources: This report utilizes data and information from the following sources:

  • CytomX Therapeutics Inc. website (www.cytomx.com)
  • SEC filings
  • Investor relations presentations
  • Industry reports
  • Financial news sources

Disclaimer: This report is intended for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investors should conduct their own due diligence before making any investment decisions.

About CytomX Therapeutics Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2015-10-08
Chairman & CEO Dr. Sean A. McCarthy DPHIL
Sector Healthcare
Industry Biotechnology
Full time employees 120
Full time employees 120

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​